Systemic reactions generally were mild and were slightly more likely among those receiving both vaccines compared with the COVID-19 mRNA booster alone.
Immunoglobulin G spike receptor binding domain antibody levels were similar after the primary series and booster dose.
mRNA-1273 continues to be efficacious at five months
Sep 27, 2021
The efficacy of mRNA-1273, the Moderna vaccine, was 93.2% for preventing COVID-19 illness and 98.2% for preventing severe COVID-19.
COVID-19 vaccine effectiveness changing with delta predominance
Sep 14, 2021
Vaccine protection against SARS-CoV-2 infection declined; protection remained higher against hospitalization, death.
Effectiveness of Ad26.COV2.S vaccine stable for six months
Mar 22, 2022
A single dose of the Johnson & Johnson vaccine was 74% and 81% effective for preventing COVID-19 infection and hospitalizations, respectively, in the U.S. before and during delta variant surge.
COVID-19 vaccine booster dose cuts infection in those 60 and older
Sep 17, 2021
A large Israeli study shows a reduction in confirmed infection and severe illness among adults 60 years of age and older.
Fourth dose of BNT162b2 offers protection against severe COVID-19
Apr 08, 2022
Protection against COVID-19 did not wane in six weeks after receipt of fourth dose of the Pfizer–BioNTech vaccine; protection against the infection waned.
NVX-CoV2373 vaccine protects against COVID-19
Dec 27, 2021
A study conducted in the U.S. and Mexico shows that the vaccine is 90% effective overall and 100% effective against moderate-to-severe disease.
ACR: Lupus patients can have low immune response to COVID-19 vaccines
Nov 15, 2021
Overall disease activity does not appear to change after vaccination, however.
No elevated risk for stroke seen after COVID-19 bivalent vaccine receipt
Mar 20, 2024
No evidence was seen for an increased risk for stroke in one- to 21-day or 22- to 42-day windows compared with a 43- to 90-day window after the vaccine.